---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-059159"
form_type: "8-K"
ticker: "BMY"
cik: "0000014272"
company_name: "BRISTOL MYERS SQUIBB CO"
filed_at: "2023-12-22T23:59:59+00:00"
generated_at: "2026-06-07T07:49:00.717399+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Bristol Myers Squibb to acquire Karuna Therapeutics for $330/share, ~$14B equity value

## Summary
- Deal valued at $14.0B equity / $12.7B net of cash; 53.4% premium to KRTX Dec 21 close.
- Karuna's lead asset KarXT for schizophrenia; PDUFA date Sept 26, 2024; also in trials for Alzheimer's psychosis.
- Expected to close H1 2024, subject to Karuna shareholder and regulatory approvals; financed with new debt.
- Non-GAAP EPS dilutive by ~$0.30 in 2024 due to financing cost; BMS cites portfolio prioritization to offset.

## SEC filing metadata
- accession: 0001140361-23-059159
- form_type: 8-K
- ticker: BMY
- cik: 0000014272
- company_name: BRISTOL MYERS SQUIBB CO
- filed_at: 2023-12-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/14272/000114036123059159/0001140361-23-059159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/14272/000114036123059159/ef20017313_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-059159
- JSON: https://secwatch.observer/filing/0001140361-23-059159.json
- Plain text: https://secwatch.observer/filing/0001140361-23-059159.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.